Valeant Pharmaceuticals Intl Inc (VRX) Rating Reiterated by Royal Bank of Canada
Royal Bank of Canada reiterated their sector perform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) in a research report report published on Wednesday, StockTargetPrices.com reports. Royal Bank of Canada currently has a C$23.00 price target on the specialty pharmaceutical company’s stock.
Separately, TD Securities raised their target price on Valeant Pharmaceuticals Intl to C$26.00 and gave the company a hold rating in a research note on Wednesday, July 12th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of C$22.50.
Shares of Valeant Pharmaceuticals Intl (TSE VRX) opened at C$19.48 on Wednesday. Valeant Pharmaceuticals Intl has a 12 month low of C$11.20 and a 12 month high of C$25.38.
In related news, Director Schutter Richard Urbain De purchased 4,900 shares of the business’s stock in a transaction on Monday, August 21st. The stock was acquired at an average price of C$14.35 per share, for a total transaction of C$70,315.00.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.